{"name":"Chugai Pharmaceutical","slug":"chugai-pharmaceutical","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"ELDECALCITOL","genericName":"ELDECALCITOL","slug":"eldecalcitol","indication":"Osteoporosis","status":"marketed"},{"name":"Tocilicumab","genericName":"Tocilicumab","slug":"tocilicumab","indication":"Other","status":"phase_1"},{"name":"rivavirin","genericName":"rivavirin","slug":"rivavirin","indication":"Other","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ocrelizumabu 200mg","genericName":"ocrelizumabu 200mg","slug":"ocrelizumabu-200mg","indication":"Rheumatoid Arthritis","status":"discontinued"}]}],"pipeline":[{"name":"ocrelizumabu 200mg","genericName":"ocrelizumabu 200mg","slug":"ocrelizumabu-200mg","phase":"discontinued","mechanism":"Ocrelizumab selectively depletes CD20+ B lymphocytes to suppress autoimmune-mediated inflammation.","indications":["Rheumatoid Arthritis"],"catalyst":""},{"name":"ELDECALCITOL","genericName":"ELDECALCITOL","slug":"eldecalcitol","phase":"marketed","mechanism":"Vitamin D3 receptor","indications":["Osteoporosis"],"catalyst":""},{"name":"Tocilicumab","genericName":"Tocilicumab","slug":"tocilicumab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"rivavirin","genericName":"rivavirin","slug":"rivavirin","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxQNDB6eldjOVM0aDk4TXo3cUNrSmZJMk9iV0RhYXljeHdhUDZHVmtmbGdjTFEzQVF0WU5aTjJRNHRXTFctUVA2QmRMdEs3TkE0Q09zNnQwbzlOcVhDODg0MjQwNF9DZFoyNS01U2wwRi00dC1GR0tPUzBRTEFPZlYzeElQOA?oc=5","date":"2026-02-17","type":"pipeline","source":"BioXconomy","summary":"Eyes on Asia: Gilead, Chugai Pharma, Eisai - BioXconomy","headline":"Eyes on Asia: Gilead, Chugai Pharma, Eisai","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxOSUlEdDByNGliMFZteEozU3Y0TC1JZUJ4MmltOGZqeENFTzI3QWNNNURMRzgxWlUzUk9saXpwbUdBZERUNGtibGtIVTlIWnl6T2xRb0trdFk1aEFJemZVWVlZYi1FYXRHRXRSNElMVFY0TlRyMXlDYXdweUw0VWwwQXl3MUNZa1RRMlhOdXh6dTRwa2VqbFpEZlliRElHalctSjd0YTlwR1lKcWU5MlROTkpnODFCZXBFbHZLX2x4cmZiU3pK?oc=5","date":"2026-02-12","type":"pipeline","source":"The Pharma Letter","summary":"Chugai’s Nicolas Henriot on agility, digital change and charting Europe’s next century - The Pharma Letter","headline":"Chugai’s Nicolas Henriot on agility, digital change and charting Europe’s next century","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQR0c2b1hLUFFsZlk4QUNSMWdhd3pfcVQzUVZQQTlUYzlYbUNDQzlGWmtmLXRLLWVma045WDZXWWRGWW9rMU5aQlNmR3lOekw3VjVDdFNPQWRoRDNXSnpfNDU5NkhiQ0Ztb1k2U2h6UzV4MmU5VDB2TnhDT25FRTlsZXl5VkItMjlYZjVKYkRydmVnSy1Ydm9vVUNxYkxmc2l2VnBFdmlrNVlUR0l4RlZuV0IyZ2JUVXBsVUYtSkNRclBvUjlweW9QSncwbXk5UFRp?oc=5","date":"2026-02-05","type":"pipeline","source":"PlasticsToday","summary":"Chugai Pharmaceutical Sustainable Blister Pack - PlasticsToday","headline":"Chugai Pharmaceutical Sustainable Blister Pack","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNS0JPTFhiT3dnY1VIcVZJYkVYbFBNMVRLMHFZVTdiNVNybnNGd1V0OW9raVBielByRU42dXItRjNZa25BU194UEYtYVJyMnRETjgzbmFMTnpoMGtMQXdQeEEydXRDSG9Ia3hDNHFpSEpBSExxblZqWjJsdlQ1OU9hdDE5eWFjUXRrS1lZV0tkSThzRkgtTGZES3F4WU9HNVVmaHZuLTRkNEw4OWw1ZWJyRXFR?oc=5","date":"2026-01-16","type":"pipeline","source":"Fierce Biotech","summary":"JPM26: Chugai chases new science and name recognition from US biopharma industry - Fierce Biotech","headline":"JPM26: Chugai chases new science and name recognition from US biopharma industry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTFBRRGlHVXFEaUhQWHNaUXVHNFFNNHQ3X0Z0enlHRS1QZWRseUVlWno2bl9DYXhFWVNYb3h3a2tmQnlMOTMxZ09lRlZhWm9DUzBkNUZsZGt0T0JxdFRYSVZXbG1qU0p4cjFlVVp2bEJ5WlJac200N2JWMA?oc=5","date":"2025-10-27","type":"pipeline","source":"Pharmaceutical Technology","summary":"Chugai to enhance kidney disease portfolio with Renalys - Pharmaceutical Technology","headline":"Chugai to enhance kidney disease portfolio with Renalys","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-25","type":"deal","source":"Pulse 2.0","summary":"Chugai Pharmaceutical To Buy Renalys Pharma, Expanding Kidney Disease Portfolio Across Asia - Pulse 2.0","headline":"Chugai Pharmaceutical To Buy Renalys Pharma, Expanding Kidney Disease Portfolio Across Asia - Pulse 2.0","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxONVhzQ2ZxYjFHdExqdDB3TzgzTHV4MGtTaFhVNm1wYUk0eU5YYzBMWk5PZmoybTJjWDIwckZVRVhxZ1Vic0loQlJvRHhvZ1EtRmZzWDFhdVFPN0l0UWlVa2otMlJidF9nQnpQNWRZVFpybWUxWmUzNlVsQ2FVY1dlaGZmRjlIcXlwTlI4ZzlUdkh1LXczdERKZFJ6TlpXTWw5UUlFSTFuZnhWaS1fZklVMXAwTTkwQQ?oc=5","date":"2025-10-24","type":"deal","source":"Fierce Pharma","summary":"Roche's Chugai strikes $200M M&A deal to take over IgAN asset in several Asian countries - Fierce Pharma","headline":"Roche's Chugai strikes $200M M&A deal to take over IgAN asset in several Asian countries","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNaWdFZHRwTEtCR0pIdXZCTndPT2p0MTFZNl9SRXhGMnhRb21FY0ktUkwwbjZ0S2xrNXFJWkJ5RlRxbHpSYXNkZ0p6WkEzNmd2cjJsZmc5XzgydEFJUWh6WVRYWVAzdzlLMXY3NWlvcldiOFY0bzRjRVZIMzhReDZzRlFQNThwMWFZS1hadnE0YlVpMzBqbHc?oc=5","date":"2025-10-24","type":"deal","source":"Yahoo Finance","summary":"Renalys Pharma to be Acquired by Chugai Pharmaceutical - Yahoo Finance","headline":"Renalys Pharma to be Acquired by Chugai Pharmaceutical","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxPZXJnVnZpRDZYOVExZExISWFBNUh1UFhOb3ZickdWVkl2Mk1STC1FcERrcmxXdlRZekROaEdLb1Jybzh3Sl9vRUNXdzJzaVRYZzVOZHhJVi1YU21VUkdwVXU3dk9kaEtkUmt0TU1GTV9EalZFUDdyOUhhZWdnNEdCMDdncVFndXdRNHVlYkQ3QURTM1MzRUNacHVueW9HTGNIVnBkSTlUSk5QT3FzV3o0OHp0RmJldkVHSFhHSHRGdm15Q2E2VnNseG9kYU54LTd6SkYxbk51WDIzbXo1LVFKYXBRcEZ1UQ?oc=5","date":"2025-10-17","type":"deal","source":"Reuters","summary":"Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma - Reuters","headline":"Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE1JRUdYQV9ieTdkTlNnVkRxb25uZnR2TGkxTHp3OHVXSWVwbFM1THQ2Y2FJVDROZW4yYjdIQ1hkRFktN1lKekpyS0VyZ053cWZlTnpxeVQ3Rjc3dXZaNExkRFd0MUZRVUdjZXRIb3Rld2E5UE5pWUluczBsSUI2OVk?oc=5","date":"2025-08-29","type":"pipeline","source":"chugai-pharm.co.jp","summary":"Revolutionizing Development Processes with Digital Power. Tackling Fluid Simulation Technology × Pharmaceuticals - chugai-pharm.co.jp","headline":"Revolutionizing Development Processes with Digital Power. Tackling Fluid Simulation Technology × Pharmaceuticals - chuga","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPWW1jc3BwY2tFdFhsTS1iRFp4a3d6UzM5U0NFQXBEVTNlRWt2eGFpUUFRd1phR2NGZk5xbzhSS2M4ZWVZVHpnenA3dV90NFlSb3BqOEtCZUZJZlBfSjFrTC0zbE5DbHBvN01lYjRTT2RVLTdfQUFWSVRtemQwX3FCX2paY0I?oc=5","date":"2025-08-08","type":"trial","source":"The Japan Times","summary":"Chugai stock drops the most since 1977 on disappointing obesity drug data - The Japan Times","headline":"Chugai stock drops the most since 1977 on disappointing obesity drug data","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxOd1hMLXpzZzhtTGFDMnFrekxtc3dZdUJXcTg4NGZUTGF2c21YS29XRVdTN1VqSTI5cGlGeEJMTGFyMlBfZTB0WGtxSG82QldBNU51NDBZTkVTR2xwOUJXY3NzRzJjVzY2UTg3QnhwN044aHhhNWFQMV91QXN4U1AxeDhwejJJcWREZWYwd05hbWEyTDd0VjVZRUN1V3pKQ3N3dTBaTjlFRi1sWE40elpBM1IxSXJjanRrcVpqTEhNcndUN19hOUNHb0RMdUNlOEJRX09UOGI3Y2ZvZk9JODVBUTg2WGxPNElBUUZSN1poMnIzUHB3YzFCTENtVlYzTjYwUXZ0RXBwdnNrbFNqMEJOeG52UmoyQQ?oc=5","date":"2025-07-07","type":"deal","source":"GlobeNewswire","summary":"Chugai and Gero Enter into Joint Research and License - GlobeNewswire","headline":"Chugai and Gero Enter into Joint Research and License","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"discontinued":1,"marketed":1,"phase_1":1,"phase_3":1},"enrichmentLevel":0,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}